Adalimumab/certolizumab pegol/infliximabPsoriasis and psoriasiform eruptions: 14 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1660卷 / 1期

关键词：

D O I：

10.1007/s40278-017-32981-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：16 / 16

相关论文

共 50 条

[1] Adalimumab/certolizumab pegol/infliximabPsoriasis: case report
Reactions Weekly, 2016, 1586 (1) : 23 - 23
[2] Adalimumab/certolizumab-pegol/infliximabPsoriasis : case report
Reactions Weekly, 2016, 1595 (1) : 15 - 15
[3] Adalimumab/etanercept/infliximabPsoriasis and psoriasiform lesions: 7 case reports
Reactions Weekly, 2013, 1450 (1) : 5 - 5
[4] Adalimumab/certolizumab pegol/etanerceptVarious infections: 5 case reports
Reactions Weekly, 2019, 1740 (1) : 16 - 16
[5] Adalimumab/certolizumab pegol/etanercept/infliximabTuberculosis and immune reconstitution inflammatory syndrome: 14 case reports
Reactions Weekly, 2016, 1600 (1) : 22 - 22
[6] Adalimumab/certolizumab pegol/infliximab/thalidomideVarious toxicities: 3 case reports
Reactions Weekly, 2014, 1530 (1) : 20 - 20
[7] Adalimumab/certolizumab pegol/infliximabDiscoid lupus erythematosus: 3 case reports
Reactions Weekly, 2020, 1813 (1) : 14 - 14
[8] Adalimumab/infliximabPsoriasis: 8 case reports
Reactions Weekly, 2008, 1183 (1) : 5 - 5
[9] Adalimumab/infliximabPsoriasis: 3 case reports
Reactions Weekly, 2006, 1128 (1) : 6 - 6
[10] Adalimumab/infliximabPsoriasis: 12 case reports
Reactions Weekly, 2008, 1190 (1) : 6 - 6

← 1 2 3 4 5 →